PAI-1, obesity, insulin resistance and risk of cardiovascular events

Thrombosis and Haemostasis

Volumn 78, Issue 1, 1997, Pages 656-660

  Juhan Vague, I ^a   Alessi, M C ^a  

^a TIMONE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

INSULIN; LIPID; PLASMINOGEN ACTIVATOR INHIBITOR 1;

ADIPOSE TISSUE; ATHEROSCLEROSIS; BLOOD LEVEL; CARDIOVASCULAR RISK; CONFERENCE PAPER; DIABETES MELLITUS; DNA POLYMORPHISM; HUMAN; INSULIN RESISTANCE; ISCHEMIC HEART DISEASE; LIPID METABOLISM; OBESITY; OMENTUM; PRIORITY JOURNAL;

EID: 0030764551     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0038-1657607     Document Type: Conference Paper

References (56)

1. Juhan-Vague I, Alessi MC. Fibrinolysis and risk of coronary artery disease: Fibrinolysis 1996; 10:127-36.
2. Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 1988; 37:1595-607.
3. Eschwege E, Richard JL, Thibult N, Ducimetière P, Warnet JM, Claude JR, Rosselin GE. Coronary heart disease mortality in relation with diabetes, blood glucose and plasma insulin levels. The Paris Prospective Study, ten years later. Horm Metab Res 1985; 15:41-6.
4. Ferrannini E, Haffner SM, Mitchell BD, Stern MP. Hyperinsulinemia. The key feature of a cardiovascular and metabolic syndrome. Diabetologia 1991; 34:416-22.
5. Desprès JP, Lamarche B, Mauriège P, Cantin B, Dagenais GR, Moorjani S, Lupien PJ. Hyperinsulinemia as an independent risk factor for ischemic heart disease. N Eng J Med 1996; 334:952-7.
6. Juhan-Vague I, Alessi MC, Vague P. Thrombogenic and fibrinolytic factors and cardiovascular risk in NIDDM. Ann Med 1996; 28:371-80.
7. Samad F, Loskutoff DJ. The fat mouse: A powerful genetic model to study the molecular mechanisms of elevated plasminogen activator inhibitor 1 in obesity/NIDDM. Thromb Haemostas (this issue).
8. Alessi MC, Peiretti F, Morange P, Henry M, Nalbone G, Juhan-Vague I. Production of plasminogen activator inhibitor 1 by human adipose tissue. Possible link between visceral fat accumulation and vascular disease. Diabetes, in press.
9. Björntorp P. "Portal" adipose tissue as a generator of risk factors for cardiovascular disease and diabetes. Arteriosclerosis 1990; 10: 493-6.
10. Larsson B, Svärdsud DK, Welin L, Wilhelmsen L, Björntorp P, Tibbin G. Abdominal adipose tissue distribution, obesity and risk of cardiovascular disease and death: 13 year follow-up of participants in the study of men born in 1913. Br Med J 1984; 288:1401-4.
11. Dawson S, Hamsten A, Wiman B, Henney A, Humphries S. Genetic variation at the plasminogen activator inhibitor-1 locus is associated with altered levels of plasma plasminogen activator inhibitor-1 activity. Arterioscler Thromb 1991; 11:183-90.
12. Ye S, Green FR, Scarabin PY, Nicaud V, Bara L, Dawson SJ, Humphries SE, Evans A, Luc G, Cambon JP, Arveiler D, Henney AM, Cambien F. The 4G/5G genetic polymorphism in the promoter of the plasminogen activator inhibitor-1 (PAI-1) associated with differences in plasma PAI-1 activity but not with risk of myocardial infarction in the ECTIM study. Thromb Haemostas 1995; 74:837-41.
13. Panahloo A, Mohamed-Ali V, Lane A, Green F, Humphries SE, Yudkin JS. Determinants of plasminogen activator 1 activity in treated NIDDM and its relation to a polymorphism in the plasminogen activator inhibitor 1 gene. Diabetes 1995; 44:37-42.
14. Eriksson P, Kallin B, van't Hooft, Bavenholm P, Hamsten A. Allele-specific increase in basal transcription of the plasminogen-activator inhibitor 1 gene is associated with myocardial infarction. Proc Natl Acad Sci USA 1995; 92:1851-5.
15. Dawson SJ, Wiman B, Hamsten A, Green F, Hamphries S, Henney AM. The two allele sequences of a common polymorphism in the promoter of the plasminogen activator inhibitor 1 (PAI-1) gene respond differently to interleukin 1 in HepG2 cells. J Biol Chem 1993; 268:10739-45.
16. Henry M, Tregouët DA, Alessi MC, Aillaud MF, Visvikis S, Siest G, Tiret L, Juhan-Vague I. Family study of metabolic and genetic determinants of PAI-1 activity and PAI-1 antigen plasma concentrations. The Stanislas cohort study. Thromb Haemostas XVIth ISTH Congress, Florence, 1997 (abst).
17. Hamsten A, De Faire U, Walldius G, Dahlen G, Szamosi A, Landou C, Blombäck M, Wiman B. Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction. Lancet 1987; 2:3-9.
18. Juhan-Vague I, Pyke SDM, Alessi MC, Jespersen J, Haverkate F, Thompson SG. Fibrinolytic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. Circulation 1996; 94:2057-63.
19. Vague P, Juhan-Vague I, Aillaud MF, Badier C, Viard R, Alessi MC, Collen D. Correlation between blood fibrinolytic activity, plasminogen activator inhibitor level, plasma insulin level and relative body weight in normal and obese subjects. Metabolism 1986; 35:250-3.
20. Juhan-Vague I, Alessi MC, Vague P. Increased plasma plasminogen activator inhibitor 1 levels. A possible link between insulin resistance and atherothrombosis. Diabetologia 1991; 34:457-62.
21. Sundell IB, Nilsson TK, Ranby M, Hallmans G, Hellsten G. Fibrinolytic variables are related to age, sex, blood pressure, and body build measurements: A cross-sectional study in Norsjö, Sweden. J Clin Epidemiol 1989; 42:719-23.
22. Nagi DK, Hendra TJ, Ryle AJ, Cooper TM, Temple RC, Clark PMS, Schneider AE, Hales CN, Yudkin JS. The relationships of concentrations of insulin, intact proinsulin and 32-33 split proinsulin with cardiovascular risk factors in type 2 (non insulin dependent) diabetic subjects. Diabetologia 1990; 33:532-7.
23. Juhan-Vague I, Thompson SG, Jespersen J. Involvement of the hemostatic system in the insulin resistance syndrome. A study of 1500 patients with angina pectoris. Arterioscler Thromb 1993; 13: 1865-73.
24. Eliasson M, Evrin PE, Lundblad D. Fibrinogen and fibrinolytic variables in relation to anthropometry, lipids and blood pressure. The Northern Sweden MONICA Study. J Clin Epidemiol 1994; 47:513-24.
25. Mc Gill JB, Schneider DJ, Arfken CL, Lucore CL, Sobel BE. Factors responsible for impaired fibrinolysis in obese subjects and NIDDM patients. Diabetes 1994; 43:104-9.
26. Gray RP, Vidya MA, Patterson DLH, Yudkin JS. Determinants of plasminogen activator inhibitor-1 activity in survivors of myocardial infarction. Thromb Haemostas 1995; 73:261-7.
27. Bavenholm P, Proudler A, Silveira A, Crook D, Blombäck M, de Faire U, Hamsten A. Relationships of insulin and intact and split proinsulin to haemostatic function in young men with and without coronary artery disease. Thromb Haemostas 1995; 73:568-75.
28. Sundell IB, Dahlgren S, Ranby M, Lundin E, Stenling R, Nilsson TK. Reduction of elevated plasminogen activator inhibitor levels during modest weight loss. Fibrinolysis 1989; 3:51-3.
29. Vague P, Juhan-Vague I, Alessi MC, Badier C, Valadier J. Metformin decreases the high plasminogen activator inhibition capacity, plasma insulin and triglyceride levels in non diabetic obese subjects. Thromb Haemostas 1987; 57:326-8.
30. Estelles A, Aznar J, Tormo G, Sapena P, Tormo V, Espana F. Influence of a rehabilitation sports program on the fibrinolytic activity of patients after myocardial infarction. Thromb Res 1989; 55:203-12.
31. Alessi MC, Juhan-Vague I, Kooistra T, Declerck PJ, Collen D. Insulin stimulates the synthesis of plasminogen activator inhibitor 1 by the human hepatocellular cell line Hep G2. Thromb Haemostas 1988; 60:491-4.
32. Stiko-Rahm A, Wiman B, Hamsten A, Nilsson J. Secretion of plasminogen activator inhibitor 1 from cultured human umbilical vein endothelial cells is induced by very low density lipoprotein. Arteriosclerosis 1990; 10:1067-73.
33. Potter Van Loon BJ, de Bart ACW, Radder JK, Frolich M, Kluft C, Meindors AE. Acute exogenous hyperinsulinemia does not result in elevation of plasma plasminogen activator inhibitor 1 concentration in humans. Fibrinolysis 1990; 4:93-4.
34. Raccah D, Alessi MC, Scelles V, Menart C, Juhan-Vague I, Vague P. Plasminogen activator inhibitor activity in various type of endogenous hypertriglyceridemia. Fibrinolysis 1993; 7:171-6.
35. Folsom AR, Qamhieh HT, Wing RR, Jeffrey RW, Stinson VL, Kuller LH, Wu KK. Impact of weight loss on plasminogen activator inhibitor (PAI-1), factor VII, and other hemostatic factors in moderately overweight adults. Arterioscler Thromb 1993; 13:162-9.
36. Alessi MC, Parrot G, Guenoun E, Scelles V, Vague P, Juhan-Vague I. Relation between plasma PAI activity and adipsin levels. Thromb Haemostas 1995; 74:1200-2.
37. Sawdey S, Loskutoff DJ. Regulation of murine type 1 plasminogen activity inhibitor (PAI-1) gene expression in vivo. Tissue specificity and induction by lipopolysaccharide, tumor necrosis factor a and transforming growth factor b. J Clin Invest 1991; 8: 1346-53.
38. Samad F, Yamamoto K, Loskutoff DJ. Distribution and regulation of plasminogen activator inhibitor 1 in murine adipose tissue in vivo. J Clin Invest 1996; 97:37-46.
39. Lundgren CH, Brown SL, Nordt TD, Sobel BE, Fujii S. Elaboration of type 1 plasminogen activator inhibitor from adipocytes. A potential pathogenetic link between obesity and cardiovascular disease. Circulation 1996; 93:106-10.
40. Samad F, Loskutoff DJ. Tissue distribution and regulation of plasminogen activator inhibitor-1 in obese mice. Mol Med 1996; 2:568-82.
41. Shimomura I, Funahashi T, Takahashi M, Maeda K, Kotani K, Nakamura T, Yamashita S, Miura M, Fukuda Y, Takemura K, Tokunaga K, Matsuzawa Y. Enhanced expression of PAI-1 in visceral fat: Possible contributor to vascular disease in obesity. Nature Med 1996; 2:800-3.
42. Vague P, Juhan-Vague I, Chabert V, Alessi MC, Atlan C. Fat distribution and plasminogen activator inhibitor activity in non diabetic obese women. Metabolism 1989; 38:913-5.
43. Landin K, Stigendal L, Eriksson E, Krotkiewski M, Risberg B, Tengborn L, Smith U. Abdominal obesity is associated with an impaired fibrinolytic activity and elevated plasminogen activator inhibitor-1. Metabolism 1990; 39:1044-8.
44. Cigolini M, Targher G, Bergamo Andreis IA, Tonoli M, Agostino G, De Sandre G. Visceral fat accumulation and its relation to plasma hemostatic factors in healthy men. Arterioscler Thromb Vasc Biol 1996; 16:368-74.
45. Henry M, Chomiki N, Scarabin PY, Alessi MC, Pereitti F, Arveiler D, Ferrieres J, Evans A, Amouyel P, Poirier O, Cambien F, Juhan-Vague I. Five frequent polymorphisms of plasminogen activator inhibitor 1 gene: Lack of association between genotypes, PAI activity and triglycerides levels in a healthy population. Arterioscler Thromb Vasc Biol, in press.
46. Mansfield MW, Strickland MH, Grant PJ. Environmental and genetic factors in relation to elevated circulating levels of plasminogen activator inhibitor 1 in caucasian patients with non insulin dependent diabetes mellitus. Thromb Haemostas 1995; 74:842-8.
47. Meade TW, Ruddock V, Stirling Y, Chakrabarti T, Miller GJ. Fibrinolytic activity, clotting factors and long-term incidence of ischaemic heart disease in the Northwick Park Heart Study. Lancet 1993; 342:1076-9.
48. Jansson JH, Nilsson TK, Olofsson BO. Tissue plasminogen activator and other risk factors as predictors of cardiovascular events in patients with sever angina pectoris. Eur Heart J 1991; 12:157-61.
49. Thompson SG, Kienast J, Pyke SDM, Haverkate F, van de Loo JCW. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. N Engl J Med 1995; 332:635-41.
50. Ridker PM, Vaughan DE, Stampfer MJ, Manson JE, Hennekens CH. Endogenous tissue type plasminogen activator and risk of myocardial infarction. Lancet 1993; 341:1165-8.
51. Cortellaro M, Cofrancesco E, Boschetti C, Mussoni L, Donati MB, Cardillo M, Catalano M, Gabrielli L, Lombardi B, Specchia G, Tarazzi L, Tremoli E, Pozzili E, Turri M, for the PLAT Group. Increased fibrin turnover and high PAI-1 activity as predictors of ischemic events in atherosclerotic patients: a case-control study. Arterioscler Thromb 1993; 13:1412-7.
52. Haverkate F, Thompson SG, Duckert F. Haemostasis factors in angina pectoris. Relation to gender, age and acute-phase reaction. Thromb Haemostas 1995; 73:561-7.
53. ECAT Angina Pectoris Study Group. ECAT Angina Pectoris Study. Baseline associations of haemostatic factors with extent of coronary arteriosclerosis and other coronary risk factors in 3000 patients with angina pectoris undergoing coronary angiography. Eur Heart J 1993; 14:8-17.
54. Bosma PJ, van den Berg EA, Kooistra T. Human plasminogen activator inhibitor 1 gene. Promoter and structural gene nucleotide sequences. J Biol Chem 1988; 263:9129-41.
55. Chandler WL, Alessi MC, Aillaud MF, Henderson P, Vague P, Juhan-Vague I. Clearance of t-PA and t-PA/PAI-1 complex: Relationship to elevated t-PA antigen in patients with high PAI-1 activity levels. Circulation, in press.
56. Charlton PA, Faint RW, Bent F, Bryans J, Mackie I, Machin S, Bevan P. A series of low molecular weight inhibitors of plasminogen activator inhibitor (PAI-1) increase fibrinolysis and protect against thrombus formation in the rat. Thromb Haemostas 1995; 73:1005 (abst).